
Wednesday, October 12, 2022 12:16:28 PM

Liked By
Spread the love. Be the first to like this post!
Recent ADMP News
- Additional Proxy Soliciting Materials (definitive) (defa14a) • Edgar (US Regulatory) • 03/17/2023 12:09:24 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/17/2023 12:07:50 PM
- Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/16/2023 08:24:01 PM
- Annual Report (10-k) • Edgar (US Regulatory) • 03/16/2023 07:59:02 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/14/2023 09:26:36 PM
- Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update • GlobeNewswire Inc. • 03/14/2023 08:01:00 PM
- Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering • GlobeNewswire Inc. • 03/14/2023 12:30:00 PM
- Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger • GlobeNewswire Inc. • 02/27/2023 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/23/2023 12:09:13 PM
- Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements • GlobeNewswire Inc. • 02/22/2023 09:01:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/14/2022 09:59:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 09:48:05 PM
- Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/14/2022 09:10:07 PM
- Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update • GlobeNewswire Inc. • 11/07/2022 09:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/04/2022 10:16:15 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/04/2022 10:09:16 AM
- Adamis Announces Review of Strategic Alternatives • GlobeNewswire Inc. • 10/03/2022 08:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/23/2022 09:08:52 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 09/23/2022 09:06:45 PM
- Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects • GlobeNewswire Inc. • 09/21/2022 11:30:00 AM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 09/20/2022 10:03:49 AM
- Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects • GlobeNewswire Inc. • 09/12/2022 08:05:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/12/2022 10:05:18 AM
- Securities Registration Statement (simplified Form) (s-3) • Edgar (US Regulatory) • 09/09/2022 09:13:00 PM
- Additional Proxy Soliciting Materials (definitive) (defa14a) • Edgar (US Regulatory) • 08/18/2022 07:09:02 PM
Metatron Releases All-in-One Artificial Intelligence Mobile Apps for iPhone and Android • MRNJ • Mar 27, 2023 9:00 AM
Memorandum of Understanding With Miranda Water Treatment Systems and Rainmaker Worldwide Inc. Extended • RAKR • Mar 27, 2023 8:50 AM
Hollywall Entertainment Inc., (OTC:HWAL) Announces the completion of its 2021 and 2020 Audit (s) • HWAL • Mar 24, 2023 12:48 PM
Glucose Health, Inc. Fiscal 2022 Annual Report • GLUC • Mar 23, 2023 3:23 PM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM